Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 7 Leukemia, Myeloid, Acute 5 Neuroblastoma 2 Neoplasm Metastasis 2 Thyroid Neoplasms 1 Sarcoma, Myeloid 1 Rhabdomyosarcoma 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pancreatic Neoplasms 1 Neoplasms 1 Myelodysplastic Syndromes 1 Melanoma 1 Hepatoblastoma 1 Gastrointestinal Stromal Tumors 1 Fibrolamellar hepatocellular carcinoma 1

Interventions

Cyclophosphamide 26 fludarabine 18 Dexamethasone 17 pembrolizumab 12 Rituximab 11 Etoposide 10 venetoclax 9 pomalidomide 9 Gemcitabine 9 fludarabine phosphate 7 daratumumab 7 Lenalidomide 7 Bortezomib 7 carfilzomib 6 obinutuzumab 5 glofitamab 5 Vincristine 5 Temozolomide 5 Prednisone 5 Nivolumab 5 Immunotherapy, Adoptive 5 Cisplatin 5 Calcium Dobesilate 5 selinexor 4 cemiplimab 4 Doxorubicin 4 Cytarabine 4 Carboplatin 4 zanubrutinib 3 ruxolitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Sorafenib × 90 days × Clear all

NCT02298348 2026-03-23

N2013-02

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Active not recruiting

Neuroblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡